Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT02599961 Terminated - Clinical trials for Glucose Transporter Type 1 Deficiency Syndrome

Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)

Start date: September 10, 2015
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the long-term safety of UX007 in Glut1 DS participants.

NCT ID: NCT02598427 Terminated - Clinical trials for HER2 Positive Untreated Metastatic Breast Cancer

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Start date: May 1, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to determine how well pertuzumab and trastuzumab works in treating breast cancer that has spread to the brain. Pertuzumab and trastuzumab are treatments that stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). Pertuzumab and trastuzumab have been found to be very effective for HER2-positive breast cancer and are FDA approved for treatment of metastatic breast cancer outside of the brain when given through the vein. This suggests that pertuzumab and trastuzumab may help shrink or stabilize HER2-positive breast cancer that has spread to the brain in this research study. In this research study, the investigators are looking to see whether pertuzumab and trastuzumab will work to decrease the size of or stabilize breast cancer that has spread to the brain.

NCT ID: NCT02598310 Terminated - Breast Cancer Clinical Trials

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

Start date: November 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of nab-PTX and trastuzumab for ER negative and HER2 positive operable (tumor size of 3cm or less and N0) breast cancer.

NCT ID: NCT02598297 Terminated - Clinical trials for Myelofibrosis With High Molecular Risk Mutations

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

ReTHINK
Start date: February 3, 2016
Phase: Phase 3
Study type: Interventional

Myelofibrosis patients with high molecular risk mutations have an intrinsically aggressive disease with increased risk of leukemic transformation and reduced overall survival. As there are no therapies currently established in the subset of high molecular risk patients with early myelofibrosis, the study aimed to evaluate ruxolitinib in this patient population.

NCT ID: NCT02597972 Terminated - Clinical trials for Closed Fracture Proximal Humerus, Four Part

Reverse Total Shoulder Arthroplasty Versus Open Reduction Internal Fixation of 3&4 Part Proximal Humerus Fractures

Start date: September 2015
Phase: N/A
Study type: Interventional

Will patients who suffer complex humerus fractures have better functional outcomes and less implant failure with shoulder replacement (reverse total shoulder arthroplasty, RTSA) compared to shoulder repair (open reduction and internal fixation, ORIF)?

NCT ID: NCT02597153 Terminated - Clinical trials for Relapsed Cutaneous T Cell Lymphom

Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

Start date: October 2015
Phase: Phase 2
Study type: Interventional

To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with relapsed cutaneous T cell lymphomasell

NCT ID: NCT02595918 Terminated - Clinical trials for Metastatic Renal Cell Carcinoma

Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery

Start date: May 19, 2016
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies the side effects of nivolumab and how well it works in treating patients with high-risk kidney cancer before surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02595840 Terminated - Clinical trials for Non-small-cell Lung Cancer With Somatic EGFR Mutations

Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)

Trans-MARBLE
Start date: November 25, 2015
Phase: Phase 2
Study type: Interventional

To compare the efficacy of afatinib maintenance with pemetrexed maintenance following induction therapy with platinum/ pemetrexed in patients with metastatic EGFR mutated non-small-cell lung cancer progressing after first-line treatment with afatinib as first tyrosine kinase inhibitor with respect to progression-free survival

NCT ID: NCT02594163 Terminated - Clinical trials for Diffuse Large B-cell Lymphoma Refractory

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin in combination with rituximab and bendamustine for the treatment of patients with relapsed or refractory CD30-positive diffuse large B-cell lymphoma (DLBCL) after failure of second-line salvage therapy or as second-line treatment in patients ineligible for autologous stem cell transplant (ASCT).

NCT ID: NCT02593851 Terminated - Clinical trials for Respiratory Syncytial Virus Infections

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

Start date: December 4, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate pharmacokinetics, safety, tolerability, antiviral activity, and impact on the clinical course of Respiratory Syncytial Virus (RSV) infection after multiple oral doses of JNJ-53718678 at different doses and/or dosing regimens in infants (greater than [>] 1 month to less than or equal to [<=] 24 months of age) who are hospitalized with RSV infection.